Disease-specific National Programmes (NTEP, NVBDCP, NLEP)
Community Medicine · National Health Programmes · lean revision notes
Disease-specific National Programmes (NTEP, NVBDCP, NLEP)
India runs vertical, disease-specific programmes for tuberculosis, vector-borne diseases and leprosy under the National Health Mission. NEET PG loves cross-programme integration — programme indicators, free-drug eligibility, named regimens, and India-specific current elimination targets. This note packs the high-yield facts you must carry into the hall.
Quick orientation to the three programmes
| Programme | Full form | Launched / renamed | Nodal disease(s) | Current India target |
|---|---|---|---|---|
| NTEP | National Tuberculosis Elimination Programme | RNTCP renamed NTEP in 2020 | Tuberculosis | TB elimination by 2025 (5 yrs ahead of SDG 2030) |
| NVBDCP | National Vector Borne Disease Control Programme | 2003–04 (merged earlier programmes) | Malaria, dengue, chikungunya, JE, kala-azar, lymphatic filariasis | Malaria-free by 2027, elimination by 2030; kala-azar elimination achieved |
| NLEP | National Leprosy Eradication Programme | 1983 (from NLCP) | Leprosy | Leprosy elimination (<1/10,000) achieved 2005; now "zero transmission" |
High-yield: RNTCP → NTEP renamed in 2020; the "Elimination" replaced "Control". The National Strategic Plan (NSP) 2017–2025 set the 2025 target, a full 5 years before the global SDG target of 2030.
NTEP — National Tuberculosis Elimination Programme
Definitions & key concepts
- Elimination of TB (programme definition) = reducing incidence to <1 case per million population. (Note: "pre-elimination" historically = <10/million; full elimination <1/million.) For the 2025 target India aims for an 80% reduction in incidence and 90% reduction in mortality vs 2015 baseline, with zero catastrophic costs to families.
- Presumptive TB (replaced the older "TB suspect") = any person with symptoms/signs suggestive of TB (cough >2 weeks, fever, weight loss, haemoptysis, etc.).
Diagnosis — investigation of choice
The programme now mandates an upfront molecular test (NAAT) as the first-line diagnostic wherever available, rather than smear microscopy.
Diagnostic flow: Presumptive TB → NAAT (CBNAAT/TrueNat) as upfront test → if MTB detected, note rifampicin resistance → Universal Drug Susceptibility Testing (UDST) for every diagnosed case → start appropriate regimen.
- CBNAAT (GeneXpert MTB/RIF) detects Mycobacterium tuberculosis and rifampicin resistance simultaneously in ~2 hours; detection limit ~130 bacilli/mL (far more sensitive than smear, which needs ~10,000/mL).
- TrueNat — indigenous, chip-based, battery-operable; used at peripheral/PHC level.
- LPA (Line Probe Assay) — detects resistance to rifampicin + isoniazid (first-line LPA) and to fluoroquinolones + second-line injectables (second-line LPA).
- Liquid culture (MGIT) is the gold standard for confirmation and DST but slow.
High-yield: UDST (Universal Drug Susceptibility Testing) — every microbiologically confirmed TB patient must have a DST done at diagnosis. This is a flagship NSP strategy.
Treatment regimens (daily, fixed-dose combination)
India shifted from thrice-weekly intermittent to daily FDC regimens for all patients. Weight-band based dosing.
| Regimen | Drugs | Intensive phase | Continuation phase |
|---|---|---|---|
| Drug-sensitive TB (new + previously treated) | 2HRZE / 4HRE | 2 months HRZE | 4 months HRE |
| Paediatric DS-TB | HRZE (E added) | 2 months | 4 months HR(E) |
| TB Preventive Treatment (TPT) | 3HP (isoniazid + rifapentine weekly ×12) or 6H | — | — |
- Note: the old "Category I/II" classification and the separate retreatment regimen (with streptomycin) have been discontinued; everyone gets the same daily HRZE-based regimen, and resistance dictates the switch.
- Drug-resistant TB: shorter all-oral BPaLM regimen (Bedaquiline + Pretomanid + Linezolid + Moxifloxacin) is now the preferred regimen for eligible MDR/RR-TB and pre-XDR — duration 6 months. Injectable kanamycin/capreomycin are essentially phased out.
High-yield: BPaLM = Bedaquiline + Pretomanid + Linezolid + Moxifloxacin — the new 6-month all-oral DR-TB regimen. Bedaquiline acts on ATP synthase.
Programme support schemes
- Ni-kshay Poshan Yojana — Direct Benefit Transfer of ₹500/month (revised from ₹500; some sources cite enhanced amounts) to every notified TB patient for nutritional support, via the Ni-kshay portal.
- Ni-kshay Mitra — community/donor adoption of TB patients (Pradhan Mantri TB Mukt Bharat Abhiyaan).
- Notification of TB is mandatory for all (public + private) under the Gazette notification; non-notification is punishable.
Key NTEP indicators
| Indicator | What it measures |
|---|---|
| Annual TB notification rate | Cases notified per 1,00,000 population |
| Treatment success rate | % of cohort cured + treatment completed |
| Presumptive TB examination rate | Programme reach/case finding |
| Initial loss to follow-up | Diagnosed but not started on treatment |
High-yield: DOT (Directly Observed Treatment) is being supplemented by digital adherence — 99DOTS (missed-call) and video-DOT. Treatment outcome cohorts: cured, treatment completed, failure, died, lost to follow-up, not evaluated.
Mnemonic for first-line TB drug toxicities — "RIPE":
- Rifampicin → orange/red secretions, hepatotoxicity, enzyme inducer
- Isoniazid → peripheral neuropathy (give pyridoxine/B6), hepatotoxicity
- Pyrazinamide → hyperuricaemia/gout, hepatotoxicity
- Ethambutol → optic neuritis (red-green colour blindness); Streptomycin → ototoxicity/nephrotoxicity (8th nerve).
NVBDCP — National Vector Borne Disease Control Programme
Umbrella programme for six vector-borne diseases: malaria, dengue, chikungunya, Japanese encephalitis (JE), lymphatic filariasis (LF), and kala-azar (visceral leishmaniasis).
Malaria
Key indicators (memorise the formulae):
| Indicator | Definition / formula |
|---|---|
| API (Annual Parasite Incidence) | (Confirmed malaria cases in 1 year ÷ population under surveillance) × 1000 |
| ABER (Annual Blood Examination Rate) | (Blood slides examined ÷ population) × 100; target ≥10% |
| SPR (Slide Positivity Rate) | (Positive slides ÷ slides examined) × 100 |
| SfR (Slide falciparum Rate) | (P. falciparum positive ÷ slides examined) × 100 |
High-yield: API is the surveillance indicator. API <1 is the cut-off used to classify low-transmission areas and is the threshold for the elimination framework (categorisation of districts into Category 0–3).
India malaria elimination timeline (NFME — National Framework for Malaria Elimination 2016–2030):
- 2022 → eliminate in all low (Category 1) and moderate transmission districts conceptually staged
- 2024 → interrupt indigenous transmission in Category 1 & 2 states
- 2027 → zero indigenous cases across India (malaria-free)
- 2030 → prevent re-establishment; certification of elimination
Treatment (drug of choice — NVBDCP guidelines):
- P. vivax: Chloroquine 25 mg/kg over 3 days + Primaquine 0.25 mg/kg/day × 14 days (radical cure — kills hypnozoites; check G6PD).
- P. falciparum: ACT (Artemisinin-based Combination Therapy). In Northeast India: Artemether–Lumefantrine; in rest of India: AS+SP (Artesunate + Sulfadoxine-Pyrimethamine) × 3 days + single-dose Primaquine 0.75 mg/kg (gametocytocidal) on day 2.
High-yield: Single low-dose primaquine in falciparum is gametocytocidal (blocks transmission); in vivax, 14-day primaquine is for radical cure (anti-hypnozoite). Check G6PD before primaquine.
Kala-azar (Visceral Leishmaniasis)
- Vector: female Phlebotomus argentipes (sandfly); parasite Leishmania donovani; reservoir is man (anthroponotic in India).
- Elimination target definition: <1 case per 10,000 population at block (PHC) level. India achieved this and the WHO validation/elimination milestone was reached around 2023–2024.
- Drug of choice: single-dose Liposomal Amphotericin B (AmBisome) 10 mg/kg IV — the backbone of the elimination strategy. Miltefosine is oral alternative.
- Incentive: cash to patients (wage loss compensation) and to ASHAs for case detection.
High-yield: Kala-azar elimination cut-off = <1 per 10,000 at block level; single-dose liposomal amphotericin B is the preferred drug under the programme.
Lymphatic Filariasis (LF)
- Aim: elimination via annual Mass Drug Administration (MDA).
- Regimen evolved to IDA / triple-drug therapy: Ivermectin + DEC + Albendazole in endemic districts; elsewhere DEC + Albendazole.
- MF rate (microfilaria rate) <1% is the key threshold to stop MDA; confirmed by Transmission Assessment Survey (TAS).
Dengue, Chikungunya, JE
- Dengue/chikungunya vector: Aedes aegypti; surveillance via sentinel hospitals + NS1 antigen / IgM ELISA.
- JE vector: Culex (vishnui group); pig = amplifying host, ardeid birds = reservoir. JE vaccine included in UIP in endemic districts.
NLEP — National Leprosy Eradication Programme
Definitions & classification
- Elimination of leprosy (as a public health problem) = prevalence <1 case per 10,000 population. India achieved this nationally in December 2005.
- WHO operational classification (for treatment) based on skin lesions:
| Type | Skin lesions | Smear |
|---|---|---|
| Paucibacillary (PB) | 1–5 lesions | Smear negative |
| Multibacillary (MB) | >5 (≥6) lesions | Smear positive (or any positive smear) |
- Ridley–Jopling spectrum (immunological): TT → BT → BB → BL → LL (tuberculoid to lepromatous; immunity decreasing, bacillary load increasing). Lepromin test positive in tuberculoid, negative in lepromatous.
Diagnosis — cardinal signs
Diagnosis is clinical; any one cardinal sign suffices:
- Hypopigmented/reddish patch with definite loss of sensation
- Thickened peripheral nerve with sensory/motor loss
- Demonstration of acid-fast bacilli in slit-skin smear
High-yield: Slit-skin smear sites and the Bacteriological Index / Morphological Index are classic. Lepromin (Mitsuda) test is NOT diagnostic — it indicates host immunity/prognosis, not infection.
Treatment — WHO Multi-Drug Therapy (MDT), free under NLEP
| Regimen | Drugs | Duration |
|---|---|---|
| Paucibacillary (PB) | Rifampicin (monthly, supervised) + Dapsone (daily) | 6 months |
| Multibacillary (MB) | Rifampicin (monthly) + Clofazimine (monthly + daily) + Dapsone (daily) | 12 months |
High-yield: Current WHO/NLEP recommends the uniform 3-drug MDT (R+C+D) for all new cases, but the classic exam answer remains PB = 2 drugs/6 months, MB = 3 drugs/12 months. Rifampicin is the most bactericidal; Clofazimine causes reddish-black skin discolouration.
Lepra reactions (often-tested complication)
| Feature | Type 1 (Reversal) | Type 2 (ENL) |
|---|---|---|
| Mechanism | Type IV (cell-mediated) | Type III (immune complex) |
| Seen in | Borderline (BT–BL) | Lepromatous (BL, LL) |
| Features | Existing lesions inflamed, nerve pain, neuritis | Crops of tender subcutaneous nodules, fever, systemic |
| Drug of choice | Corticosteroids (prednisolone) | Thalidomide (or steroids; clofazimine high dose) |
High-yield: ENL (Erythema Nodosum Leprosum) = Type 2 reaction = Type III hypersensitivity, drug of choice thalidomide (contraindicated in pregnancy — phocomelia). Type 1 reversal reaction = Type IV → steroids.
NLEP key strategies & indicators
- ANCDR (Annual New Case Detection Rate) per 1,00,000 — primary indicator now (since prevalence is low).
- Grade-2 disability (G2D) rate — visible deformity at diagnosis; a marker of late detection.
- PEP (post-exposure prophylaxis) with single-dose rifampicin (SDR) for contacts.
- Sparsh Leprosy Awareness Campaign, Leprosy Case Detection Campaigns (LCDC).
Cross-programme integration table (NEET PG favourite)
| Parameter | NTEP | NVBDCP (malaria) | NLEP |
|---|---|---|---|
| Key indicator | Notification rate, treatment success | API (cases/1000) | ANCDR, G2D rate |
| Elimination cut-off | <1 case/million | malaria-free (zero indigenous) | <1/10,000 |
| India target year | 2025 | 2027 (free), 2030 (elim) | achieved 2005; now zero transmission |
| Investigation of choice | CBNAAT/NAAT | RDT/microscopy | slit-skin smear (clinical dx) |
| Flagship drug/regimen | BPaLM, daily HRZE | ACT (AS+SP) | MDT (R/C/D) |
| Free drug delivery | Yes | Yes | Yes |
High-yield: Note the different denominators: TB elimination is per million, leprosy & kala-azar are per 10,000, malaria API is per 1000. Examiners deliberately swap these.
Recently asked / exam angle
- RNTCP renamed NTEP in which year? → 2020.
- Upfront diagnostic test for TB under NTEP → NAAT (CBNAAT/TrueNat), not sputum microscopy.
- BPaLM full form / which drug is ATP synthase inhibitor → Bedaquiline.
- API formula and cut-off (<1) for malaria elimination categorisation.
- Drug of choice for kala-azar elimination → single-dose liposomal amphotericin B; elimination cut-off <1/10,000 at block level.
- Radical cure of P. vivax → primaquine ×14 days (check G6PD); single low-dose primaquine in falciparum is gametocytocidal.
- PB vs MB leprosy classification (1–5 vs ≥6 lesions) and MDT duration (6 vs 12 months).
- ENL = Type 2 lepra reaction = Type III hypersensitivity → thalidomide; reversal = Type 1 = Type IV → steroids.
- Cardinal signs of leprosy (any one diagnostic); lepromin test is prognostic, not diagnostic.
- Ni-kshay Poshan Yojana nutritional DBT for notified TB patients.
- TB notification is mandatory for private practitioners (Gazette notification).
- Vector pairings: malaria–Anopheles; kala-azar–Phlebotomus argentipes; filaria–Culex quinquefasciatus; dengue–Aedes aegypti; JE–Culex.
Rapid revision
- RNTCP → NTEP in 2020; TB elimination target 2025 (80% incidence ↓, 90% mortality ↓ vs 2015).
- TB elimination cut-off = <1 case per million; investigation of choice = upfront NAAT (CBNAAT/TrueNat); UDST for all.
- DS-TB regimen = daily FDC 2HRZE/4HRE; Category I/II abolished.
- DR-TB → 6-month all-oral BPaLM (Bedaquiline–Pretomanid–Linezolid–Moxifloxacin); bedaquiline hits ATP synthase.
- Ni-kshay Poshan Yojana = nutritional DBT to every notified TB patient; notification is mandatory.
- API = (confirmed cases/population) × 1000; API <1 is the elimination/categorisation threshold; ABER target ≥10%.
- India aims malaria-free by 2027, elimination by 2030 (NFME 2016–2030).
- P. vivax → CQ + primaquine 14 days (radical cure, G6PD check); P. falciparum → ACT (AS+SP) + single-dose primaquine (gametocytocidal); NE India uses AL.
- Kala-azar elimination = <1/10,000 at block level; DOC = single-dose liposomal amphotericin B; vector Phlebotomus argentipes.
- LF → annual MDA (IDA: ivermectin+DEC+albendazole); stop when MF rate <1% confirmed by TAS.
- Leprosy elimination = <1/10,000 (achieved 2005); PB = 1–5 lesions/6 months, MB = ≥6 lesions/12 months; uniform 3-drug MDT now recommended.
- ENL = Type 2 = Type III HS → thalidomide; reversal = Type 1 = Type IV → steroids; lepromin test = prognostic, not diagnostic.